What is 'Phase 2'

Phase 2 is the second phase of clinical trials or studies for an experimental new drug, in which the focus of the drug is on its effectiveness. The Center for Drug Evaluation and Research, or CDER, a division of the U.S. Food and Drug Administration, oversees these clinical trials.

Phase 2 trials typically involve hundreds of patients who have the disease or condition that the drug candidate seeks to treat. The main objective of Phase 2 trials is to obtain data on whether the drug actually works in treating a disease or indication, which is generally achieved through controlled trials that are closely monitored, while safety and side-effects also continue to be studied.

BREAKING DOWN 'Phase 2'

Phase 2 studies also aim to establish the most effective dosage for the drug, and the optimum delivery method. Phase 2 trials usually form the biggest stumbling block in the development of a new drug.

Phase 2 trials are typically constructed as double blind, randomized, placebo-controlled studies. This means that some of the patients enrolled in the study will receive the drug candidate, while others will receive a placebo or a different drug. The assignment is done on a random basis and neither the participant nor the clinical investigator knows whether the participant will be receiving the drug or the placebo. This randomness and anonymity is rigorously enforced to prevent bias in the studies.

Success rate and stock impact of phase 2 trials

Phase 2 trials are considered successful when analysis of the data from enrolled participants reveals that the experimental drug works in treating the disease or indication. Patients who have received the experimental drug should have better clinical outcomes on a statistically significant basis than those who received the placebo or the alternative drug. If Phase 2 trials are successful, the drug proceeds to Phase 3 studies.  

Phase 2 studies only commence if Phase 1 studies do not reveal unduly high toxicity or other safety risks of the experimental drug. While up to a third of drugs in Phase 1 studies do not progress to the Phase 2 stage because they are not safe enough, the odds of a drug progressing from Phase 2 to Phase 3 trials are even lower, about 32 percent to 39 percent.

Because of the relatively low rate of success at the Phase 2 stage, market reaction to a successful Phase 2 outcome is generally rewarded with significant stock price appreciation for the company developing the drug. The degree of stock appreciation depends on a number of factors including: the prevailing environment for equities in general and healthcare stocks in particular, the disease or indication that the drug aims to treat, the strength of the Phase 2 results, and price movement in the stock prior to the release of Phase 2 results.

RELATED TERMS
  1. Clinical Trials

    Clinical trials are studies of human volunteers for the purpose ...
  2. Phase 4

    Phase 4 refers to the final stage of new drug testing, which ...
  3. New Drug

    New drug is an original or innovative medication or therapy that ...
  4. New Drug Application (NDA)

    The New Drug Application (NDA) is the formal final step taken ...
  5. Food And Drug Administration (FDA)

    The Food and Drug Administration is a government agency that ...
  6. Orange Book

    The Orange Book is a list of drugs that the U.S. Food and Drug ...
Related Articles
  1. Investing

    It's No Accident That Drugs Are Expensive

    Branded drugs are expensive in large part because it's expensive and risky to develop them
  2. Insights

    How Pharmaceutical Companies Price Their Drugs

    Learn about how pharmaceutical companies price drugs, why prices are often very high, and why it can be difficult to settle on a suitable price.
  3. Investing

    Corbus Gets FDA Green Light for Phase 3 Drug Study

    Corbus stock spiked after it announced that the FDA approved an upcoming Phase 3 drug study.
  4. Investing

    Drug Giants May Benefit From China Drug Inclusion

    Pharma giants may see higher sales as the Chinese government subsidizes expensive prescription drugs.
  5. Personal Finance

    Supplemental Indications: The Promising Pharma Stream (GILD)

    While supplemental indications can lead to more revenues and wider treatment options, they may add substantially to the drug cost for the end patients.
  6. Insurance

    The Cancer (and Other Drug) Shortage

    Your doctor may not tell you, but even in the U.S., life-saving drugs can be in short supply. Here's what to know and do.
  7. Investing

    Where Does the US Get Its Supply of Drugs?

    Despite increasing demands for local production, the US imports only a small portion of its drugs.
  8. Insights

    Firdapse Fuels Catalyst Pharmaceutical's Gains (CPRX)

    Significant findings in phase 3 clinical trials suggest FDA approval is imminent, buoying investor confidence.
  9. Investing

    Cost of Old Cancer Drugs Rises in EU Amid Outcry

    The prices of several off-patent cancer drugs have soared more than 100% in Europe.
  10. Investing

    Drug Approvals Fell to Six-Year Low in 2016

    New drug approvals dropped to modest levels in 2016 following highs in 2014 and 2015.
RELATED FAQS
  1. Do financial advisors get drug tested?

    Financial advisor regulatory bodies do not require drug testing, but many individual firms that hire advisors do. Read Answer >>
  2. Can your insurance company drug test you?

    Learn why insurance companies conduct drug tests and how a lifestyle free of drugs can save you big money on health and life ... Read Answer >>
  3. Who are Pfizer's (PFE) main competitors?

    Learn about Pfizer's place in the pharmaceutical industry, and find out which major drug manufacturers are among its main ... Read Answer >>
Trading Center